Results may seem promising, but further studies, including double-blind randomized controlled trials (RCTs), are needed to determine if exogenous adiponectin administration could be a safe and effective treatment for obesity and related metabolic disorders in humans. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.